With more than 40 states reporting an increase in overdose deaths during the COVID-19 pandemic, the American Medical Association, in partnership with the firm Manatt Health, has published an update to its National Roadmap on State-Level Efforts to End the Nation’s Drug Overdose Epidemic.
Spark Biomedical, a Texas-based medical device company, announced that the FDA has granted 510(k) clearance for its Sparrow Therapy System, a wearable neurostimulation device for the treatment of opioid withdrawal.
While providers wait for vaccines to slow the COVID-19 pandemic and better treatments to reduce the death toll among those infected, there are steps that can be taken to help address the “other” surge—in the opioid crisis.
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a media report.
Psychosocial factors are clearly important in determining health status and driving primary care visits. If we are prepared, the primacy of behavior change in health improvement could place our field on the frontlines of healthcare delivery.
The “primary care psychologist” (PC-Psy) concept springs from a newly conceived framework in which a psychologist and a primary care physician are business partners. While this depiction is not currently in existence, there are no major impediments to this PC-Psy role becoming real.